Vaccination against respiratory Pseudomonas aeruginosa infection

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 14-20

  Grimwood, Keith ^a,b,c   Kyd, Jennelle M ^d   Owen, Suzzanne J ^a,b   Massa, Helen M ^a,b   Cripps, Allan W ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Mucosal immunity; Oral immunisation; P. aeruginosa; Vaccine

Indexed keywords

PSEUDOMONAS VACCINE;

ANIMAL; ANIMAL MODEL; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MUCOSAL DRUG ADMINISTRATION; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VACCINATION;

ADMINISTRATION, MUCOSAL; ANIMALS; HUMANS; MODELS, ANIMAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; RESPIRATORY TRACT INFECTIONS; VACCINATION;

EID: 84949131641     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34296     Document Type: Review

References (60)

1. Kidd T, Whiley D, Bell S, Grimwood K. Pseudomonas. In: Liu D, ed. Molecular detection of human bacterial pathogens. Boca Raton, FL.: CRC Press, 2011:1009-21.
2. Klockgether J, Cramer N, Wiehlmann L, Davenport CF, Tümmler B. Pseudomonas aeruginosa Genomic Structure and Diversity. Front Microbiol 2011; 2:150; PMID:21808635; http://dx.doi.org/10.3389/fmicb.2011.00150
3. Pier G, Ramphal R. Pseudomonas aeruginosa. In: Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2010:2835-60.
4. Ciofu O, Hansen CR, Høiby N. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med 2013; 19:251-8; PMID:23449384; http://dx.doi.org/10.1097/MCP.0b013e32835f1afc
5. McShane PJ, Naureckas ET, Tino G, Strek ME. Noncystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188:647-56; PMID:23898922
6. Desai H, Eschberger K, Wrona C, Grove L, Agrawal A, Grant B, Yin J, Parameswaran GI, Murphy T, Sethi S. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11:303-9; PMID:24423399; http://dx.doi.org/10.1513/AnnalsATS.201310-350OC
7. Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 2013; 67:159-73; PMID:23620179; http://dx.doi.org/10.1111/2049-632X.12033
8. Crabbé A, Ledesma MA, Nickerson CA. Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa. Pathog Dis 2014; 71:1-19; PMID:24737619; http://dx.doi.org/10.1111/2049-632X.12180
9. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14; PMID:23221186; http://dx.doi.org/10.1086/668770
10. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, et al.; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9; PMID:19952319; http://dx.doi.org/10.1001/jama.2009.1754
11. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 2011; 139:1172-85; PMID:21540216; http://dx.doi.org/10.1378/chest.10-0167
12. Staudinger BJ, Muller JF, Halldórsson S, Boles B, Angermeyer A, Nguyen D, Rosen H, Baldursson O, Gottfredsson M, Gudmundsson GH, et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189:812-24; PMID:24467627; http://dx.doi.org/10.1164/rccm.201312-2142OC
13. Rello J, Rué M, Jubert P, Muses G, Soñora R, Vallés J, Niederman MS. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862-7; PMID:9366771; http://dx.doi.org/10.1097/00003246-199711000-00026
14. Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010; 38:25-32; PMID:20012908; http://dx.doi.org/10.1007/s15010-009-9145-9
15. Sanders DB, Li Z, Laxova A, Rock MJ, Levy H, Collins J, Ferec C, Farrell PM. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 2014; 11:63-72; PMID:24261460; http://dx.doi.org/10.1513/AnnalsATS.201309-303OC
16. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H; ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J 2014; 43:125-33; PMID:23598952; http://dx.doi.org/10.1183/09031936.00166412
17. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34:843-9; PMID:19357155
18. Almagro P, Salvadó M, Garcia-Vidal C, Rodríguez-Carballeira M, Cuchi E, Torres J, Heredia JL. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012; 84:36-43; PMID:21996555
19. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014; 11:404-6; PMID:24673696; http://dx.doi.org/10.1513/AnnalsATS.201311-405PS
20. Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 2010; 15:1037-56; PMID:20723140; http://dx.doi.org/10.1111/j.1440-1843.2010.01819.x
21. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9:32; PMID:21463524; http://dx.doi.org/10.1186/1741-7015-9-32
22. Hurley MN, Cámara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J 2012; 40:1014-23; PMID:22743672; http://dx.doi.org/10.1183/09031936.00042012
23. Vincent JL. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol 2014; 9:457-63; PMID:24810345; http://dx.doi.org/10.2217/fmb.14.10
24. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012; 18:509-19; PMID:22481418; http://dx.doi.org/10.1038/nm.2715
25. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373:1891-904; PMID:19403164; http://dx.doi.org/10.1016/S0140-6736(09)60327-5
26. Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012; 11:363-82; PMID:22917571; http://dx.doi.org/10.1016/j.jcf.2012.07.003
27. Lavoie EG, Wangdi T, Kazmierczak BI. Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect 2011; 13:1133-45; PMID:21839853; http://dx.doi.org/10.1016/j.micinf.2011.07.011
28. Yang L, Jelsbak L, Molin S. Microbial ecology and adaptation in cystic fibrosis airways. Environ Microbiol 2011; 13:1682-9; PMID:21429065; http://dx.doi.org/10.1111/j.1462-2920.2011.02459.x
29. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 2012; 10:841-51; PMID:23147702; http://dx.doi.org/10.1038/nrmicro2907
30. Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med 2014; 190:289-97; PMID:24937177
31. Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008; 26:1011-24; PMID:18242792; http://dx.doi.org/10.1016/j.vaccine.2007.12.007
32. Sedlak-Weinstein E, Cripps AW, Kyd JM, Foxwell AR. Pseudomonas aeruginosa: the potential to immunise against infection. Expert Opin Biol Ther 2005; 5:967-82; PMID:16018741; http://dx.doi.org/10.1517/14712598.5.7.967
33. Thomas LD, Kyd JM, Bastin DA, Dunkley ML, Cripps AW. Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 2003; 37:155-60; PMID:12832119; http://dx.doi.org/10.1016/S0928-8244(03)00073-7
34. Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2012; 186:420-7; PMID:22723292; http://dx.doi.org/10.1164/rccm.201202-0182OC
35. Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines 2014; 13:507-19; PMID:24575895; http://dx.doi.org/10.1586/14760584.2014.890053
36. Clancy RL, Dunkley M. Acute exacerbations in COPD and their control with oral immunization with non-typeable haemophilus influenzae. Front Immunol 2011; 2:7; PMID:22566798
37. Cripps AW, Dunkley ML, Clancy RL. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun 1994; 62:1427-36; PMID:8132349
38. Macmillan H, Norimine J, Brayton KA, Palmer GH, Brown WC. Physical linkage of naturally complexed bacterial outer membrane proteins enhances immunogenicity. Infect Immun 2008; 76:1223-9; PMID:18086812; http://dx.doi.org/10.1128/IAI.01356-07
39. Lee J-S, Heo Y-J, Lee JK, Cho Y-H. KatA, the major catalase, is critical for osmoprotection and virulence in Pseudomonas aeruginosa PA14. Infect Immun 2005; 73:4399-403; PMID:15972537; http://dx.doi.org/10.1128/IAI.73.7.4399-4403.2005
40. Thomas LD, Dunkley ML, Moore R, Reynolds S, Bastin DA, Kyd JM, Cripps AW. Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung. Vaccine 2000; 19:348-57; PMID:10930690; http://dx.doi.org/10.1016/S0264-410X(00)00146-8
41. Elkins JG, Hassett DJ, Stewart PS, Schweizer HP, McDermott TR. Protective role of catalase in Pseudomonas aeruginosa biofilm resistance to hydrogen peroxide. Appl Environ Microbiol 1999; 65:4594-600; PMID:10508094
42. Hassett DJ, Ma J-F, Elkins JG, McDermott TR, Ochsner UA, West SEH, Huang CT, Fredericks J, Burnett S, Stewart PS, et al. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol 1999; 34:1082-93; PMID:10594832; http://dx.doi.org/10.1046/j.1365-2958.1999.01672.x
43. Andrade J, Karmali A, Carrondo MA, Frazão C. Structure of amidase from Pseudomonas aeruginosa showing a trapped acyl transfer reaction intermediate state. J Biol Chem 2007; 282:19598-605; PMID:17442671; http://dx.doi.org/10.1074/jbc.M701039200
44. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, Hoffman LR, Jones G, Allen CE, Patel N, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros 2011; 10:357-65; PMID:21664196; http://dx.doi.org/10.1016/j.jcf.2011.05.002
45. Reid DW, Latham R, Lamont IL, Camara M, Roddam LF. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2013; 12:688-99; PMID:23706827; http://dx.doi.org/10.1016/j.jcf.2013.03.008
46. Deschaght P, Schelstraete P, Van Simaey L, Vanderkercken M, Raman A, Mahieu L, Van Daele S, De Baets F, Vaneechoutte M. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS One 2013; 8:e79010; PMID:24312174; http://dx.doi.org/10.1371/journal.pone.0079010
47. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187:1118-26; PMID:23348972; http://dx.doi.org/10.1164/rccm.201210-1937OC
48. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 2014; 11:425-34; PMID:24673698; http://dx.doi.org/10.1513/AnnalsATS.201311-395FR
49. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186:657-65; PMID:22744718; http://dx.doi.org/10.1164/rccm.201203-0487OC
50. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416:740-3; PMID:11961556; http://dx.doi.org/10.1038/416740a
51. Kyd JM, McGrath J, Krishnamurthy A. Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. Curr Drug Targets 2011; 12:521-30; PMID:21194403; http://dx.doi.org/10.2174/138945011794751519
52. Schuster M, Greenberg EP. A network of networks: quorum-sensing gene regulation in Pseudomonas aeruginosa. Int J Med Microbiol 2006; 296:73-81; PMID:16476569; http://dx.doi.org/10.1016/j.ijmm.2006.01.036
53. Pearson JP, Feldman M, Iglewski BH, Prince A. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun 2000; 68:4331-4; PMID:10858254; http://dx.doi.org/10.1128/IAI.68.7.4331-4334.2000
54. Rumbaugh KP, Griswold JA, Iglewski BH, Hamood AN. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect Immun 1999; 67:5854-62; PMID:10531240
55. Lazenby JJ, Griffin PE, Kyd J, Whitchurch CB, Cooley MA. A quadruple knockout of lasIR and rhlIR of Pseudomonas aeruginosa PAO1 that retains wild-type twitching motility has equivalent infectivity and persistence to PAO1 in a mouse model of lung infection. PLoS One 2013; 8:e60973; PMID:23593362; http://dx.doi.org/10.1371/journal.pone.0060973
56. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol 2006; 296:149-61; PMID:16503194; http://dx.doi.org/10.1016/j.ijmm.2006.02.005
57. Kaufmann GF, Sartorio R, Lee SH, Mee JM, Altobell LJ 3rd, Kujawa DP, Jeffries E, Clapham B, Meijler MM, Janda KD. Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc 2006; 128:2802-3; PMID:16506750; http://dx.doi.org/10.1021/ja0578698
58. Miyairi S, Tateda K, Fuse ET, Ueda C, Saito H, Takabatake T, Ishii Y, Horikawa M, Ishiguro M, Standiford TJ, et al. Immunization with 3-oxodo-decanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J Med Microbiol 2006; 55:1381-7; PMID:17005787; http://dx.doi.org/10.1099/jmm.0.46658-0
59. Cripps AW, Peek K, Dunkley M, Vento K, Marjason JK, McIntyre ME, Sizer P, Croft D, Sedlak-Weinstein L. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun 2006; 74:968-74; PMID:16428742; http://dx.doi.org/10.1128/IAI.74.2.968-974.2006
60. Clancy R, Pang G, Dunkley M, Cripps A. Control of bacterial colonisation of the respiratory tract mucosa in man. In: Alan J Husband, Kenneth W Beagley, Robert L Clancy, Andrew M Collins, Allan W Cripps, Emery DL, eds. Mucosal Solutions: Advances in mucosal immunology. Sydney, Australia: University of Sydney, 1997:261-8.